Literature DB >> 30098035

Upper Airway Stimulation in Patients With Obstructive Sleep Apnea and an Elevated Body Mass Index: A Multi-institutional Review.

Colin Huntley1, Armin Steffen2, Karl Doghramji3, Benedikt Hofauer4, Clemens Heiser4, Maurits Boon1.   

Abstract

OBJECTIVES/HYPOTHESIS: An elevated body mass index (BMI) influences the severity of disease and treatment options utilized for obstructive sleep apnea (OSA). With this study, we aim to evaluate a cohort of patients undergoing upper airway stimulation (UAS) for treatment of OSA and assess the impact of BMI on surgical and quality of life outcomes.
METHODS: We designed a case-control, retrospective review, of all patients undergoing UAS at two academic institutions between 2014 and 2017. We compare those with an elevated BMI to those without. We included patients with moderate-severe OSA, who were unable to tolerate therapy with continuous positive airway pressure (CPAP), were treated with UAS, and had a postoperative sleep study performed. We evaluated postoperative sleep study data including apnea-hypopnea index (AHI), O2 desaturation nadir, rate of cure, and rate of success in those with an elevated BMI to those without an elevated BMI. Success was defined as a drop in the postoperative AHI by 50% compared to the preoperative value and to less than 20. We also assessed daytime sleepiness using the Epworth Sleepiness Scale.
RESULTS: When defining an elevated BMI as greater than 32, we found no difference between elevated and nonelevated BMI cohorts in postoperative AHI, O2 desaturation nadir, daytime sleepiness, rate of surgical success, or rate of cure.
CONCLUSIONS: Patients with obstructive sleep apnea, unable to tolerate CPAP, and with an elevated BMI can be successfully treated with upper airway stimulation therapy. LEVEL OF EVIDENCE: 3. Laryngoscope, 128:2425-2428, 2018.
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Obstructive sleep apnea; sleep apnea; upper airway stimulation

Mesh:

Year:  2018        PMID: 30098035     DOI: 10.1002/lary.27426

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  What makes the responder to upper airway stimulation in obstructive sleep apnea patients with positive airway pressure failure?

Authors:  Armin Steffen
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Therapeutic Positive Airway Pressure Level Predicts Response to Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea.

Authors:  Clara H Lee; Everett G Seay; Benjamin K Walters; Nicholas J Scalzitti; Raj C Dedhia
Journal:  J Clin Sleep Med       Date:  2019-08-15       Impact factor: 4.062

Review 3.  Hypoglossal Nerve Stimulation in the Treatment of Obstructive Sleep Apnea: Patient Selection and New Perspectives.

Authors:  Peter M Baptista; Andrea Costantino; Antonio Moffa; Vittorio Rinaldi; Manuele Casale
Journal:  Nat Sci Sleep       Date:  2020-02-13

4.  Evaluation of pharyngeal airway volume for different dentofacial skeletal patterns using cone-beam computed tomography.

Authors:  Yu-Chuan Tseng; Feng-Chun Tsai; Szu-Ting Chou; Chung-Yao Hsu; Jung-Hsuan Cheng; Chun-Ming Chen
Journal:  J Dent Sci       Date:  2020-08-16       Impact factor: 2.080

5.  Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

Review 6.  Hypoglossal nerve stimulation for obstructive sleep apnea: updated position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery.

Authors:  Armin Steffen; Clemens Heiser; Wolfgang Galetke; Simon-Dominik Herkenrath; Joachim T Maurer; Eck Günther; Boris A Stuck; Holger Woehrle; Jan Löhler; Winfried Randerath
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-21       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.